Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 74 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;pO4hKSzVyPUCuNFYyKM7:TR?= M1uwWXNCVkeHUh?=
ALL-PO M1TITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwME[zOVUh|ryP MoHZV2FPT0WU
697 M3LoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DNNGlEPTB;MD6wPVk4PiEQvF2= NUD1bVBIW0GQR1XS
NCI-H748 NXu5OlJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT2TWM2OD1yLkGwN|M1KM7:TR?= MoHuV2FPT0WU
NKM-1 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMUC5NVIh|ryP MUTTRW5ITVJ?
ES1 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fHWmlEPTB;MD6xNVI2PSEQvF2= NEjlXoJUSU6JRWK=
NCI-H1963 M1Gx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJZZlKSzVyPUCuNVE2PzlizszN MWTTRW5ITVJ?
NCI-H1417 NYX2XIttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXLUHNKSzVyPUCuNVI6PzRizszN MVrTRW5ITVJ?
NEC8 NH\BZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\jW2lEPTB;MD6xN|UzPyEQvF2= MVTTRW5ITVJ?
CRO-AP2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jpVWlEPTB;MD6xOlg5QSEQvF2= MnnsV2FPT0WU
A3-KAW NFWwd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4PGlEPTB;MD6xO|YzPyEQvF2= M4TsU3NCVkeHUh?=
SF539 NV\xW4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfVUGd{UUN3ME2wMlE6PTl|IN88US=> NXjHO4hDW0GQR1XS
NOS-1 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMUm2NVkh|ryP Mn3UV2FPT0WU
NTERA-S-cl-D1 M1S5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMkCxNVMh|ryP MmPyV2FPT0WU
COR-L88 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uxfmlEPTB;MD6yNlk2QSEQvF2= M4HVTnNCVkeHUh?=
EM-2 NEjqXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMkSwO|kh|ryP NY\KTXZ[W0GQR1XS
KARPAS-45 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W3UWlEPTB;MD6yO|g{OyEQvF2= NUDxeFhWW0GQR1XS
DSH1 NFjhbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PKWmlEPTB;MD6yPFcxQCEQvF2= NWXXPJNMW0GQR1XS
HT-144 NWHneZZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILUOJFKSzVyPUCuN|AzPTZizszN M{\RN3NCVkeHUh?=
ATN-1 NEXGepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwM{C1O|Yh|ryP MnS2V2FPT0WU
HEL NFTpSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rxfmlEPTB;MD6zNVM1QCEQvF2= NW\1NmtpW0GQR1XS
NB12 NVfIXVZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwM{G3OVYh|ryP NHvrTYpUSU6JRWK=
LU-139 NFm0R3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3CdYZKSzVyPUCuN|M2OSEQvF2= MnKzV2FPT0WU
J-RT3-T3-5 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX3e2hKSzVyPUCuN|M4OTZizszN NF2ze2xUSU6JRWK=
MOLT-13 MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrGToxKSzVyPUCuN|M5OSEQvF2= MoDkV2FPT0WU
SR NXG0VFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17GTGlEPTB;MD6zOFI3OSEQvF2= MVrTRW5ITVJ?
CMK NHOzR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KwTmlEPTB;MD6zOVczPyEQvF2= MkPiV2FPT0WU
ES8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTQTWM2OD1yLkO2NFIzKM7:TR?= MUTTRW5ITVJ?
LB647-SCLC M2HtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP5dXJKSzVyPUCuN|Y4OyEQvF2= MlHlV2FPT0WU
TE-8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwM{[5N|Uh|ryP M3TmNHNCVkeHUh?=
BV-173 M4LyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LQfmlEPTB;MD6zO|EzOSEQvF2= NFPmfY1USU6JRWK=
DEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwM{e0PFch|ryP M1fvUHNCVkeHUh?=
ARH-77 NFH0Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq0TWM2OD1yLkO4NVk{KM7:TR?= M{CxcnNCVkeHUh?=
NCCIT MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKz[YRiUUN3ME2wMlM5PjR7IN88US=> MkC1V2FPT0WU
RPMI-8402 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljRTWM2OD1yLkO4O|AyKM7:TR?= MofJV2FPT0WU
MONO-MAC-6 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ITWM2OD1yLkO4O|c3KM7:TR?= MVfTRW5ITVJ?
SK-MM-2 NHLJNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{m4Olgh|ryP NVLaOGVsW0GQR1XS
CHP-126 NVrxeoo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHhc4ZKSzVyPUCuOFAzOzFizszN MkXaV2FPT0WU
A101D NUn5fWNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP1RnNKSzVyPUCuOFA{KM7:TR?= MknMV2FPT0WU
SCH MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzHTWM2OD1yLkSwN|QzKM7:TR?= M1rDOHNCVkeHUh?=
NMC-G1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwNECzOlch|ryP M2fjd3NCVkeHUh?=
NCI-H209 NXTreVZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKwN3VKSzVyPUCuOFA3OTNizszN MlviV2FPT0WU
MOLT-16 M2P2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ToZ2lEPTB;MD60NVAyPyEQvF2= MUTTRW5ITVJ?
RPMI-6666 M3nxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL2VJZIUUN3ME2wMlQyOTJizszN NIDaW4dUSU6JRWK=
OPM-2 NFXvSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLETWM2OD1yLkSxOVE{KM7:TR?= MYfTRW5ITVJ?
MRK-nu-1 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f4OWlEPTB;MD60N|E2OyEQvF2= MULTRW5ITVJ?
BC-1 NHyxZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7MT2lKSzVyPUCuOFM1ODNizszN NFK0N25USU6JRWK=
MHH-NB-11 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwNEO0OVMh|ryP MVzTRW5ITVJ?
Ramos-2G6-4C10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPXU4JoUUN3ME2wMlQ{QDl5IN88US=> M3nNZXNCVkeHUh?=
LS-513 NIG5SmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D2fGlEPTB;MD60OFUxOSEQvF2= NH;LN5hUSU6JRWK=
K5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HqVmlEPTB;MD60O|AzPSEQvF2= NEfyV3JUSU6JRWK=
HOP-62 NV:5N2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH4bpFKSzVyPUCuOFg{PThizszN NXqxTWpPW0GQR1XS
NCI-H187 NEj3SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnqXVFKSzVyPUCuOFkzOjdizszN NXm2N4Y1W0GQR1XS
BE-13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwNEm2OlEh|ryP MofEV2FPT0WU
HC-1 NXzC[3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TvdWlEPTB;MD61NFQ4OyEQvF2= NIj4endUSU6JRWK=
ACN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHWXI9KSzVyPUCuOVExOjhizszN M4LUWnNCVkeHUh?=
HCC1599 M2jXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwNUG1O{DPxE1? NHS4bnZUSU6JRWK=
MV-4-11 M3vLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnhTWM2OD1yLkWzNFQyKM7:TR?= M3n0WnNCVkeHUh?=
LC-2-ad NHu3boVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrBTWM2OD1yLkWzOlY{KM7:TR?= NHLu[IhUSU6JRWK=
HL-60 NWPoTpNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LJbGlEPTB;MD61OFI3OSEQvF2= M{K3R3NCVkeHUh?=
NB17 NELDXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxVYFKSzVyPUCuOVQ{QCEQvF2= NGjMeHdUSU6JRWK=
TE-1 NF;JfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwNUWzNFYh|ryP M1zxS3NCVkeHUh?=
NCI-H524 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3tUVl2UUN3ME2wMlU2PDBzIN88US=> NX\sXIVvW0GQR1XS
MZ7-mel M36w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwNU[xNFUh|ryP M2\NZXNCVkeHUh?=
L-363 NH;XNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XlPWlEPTB;MD61OlY2PyEQvF2= NYjuS5ljW0GQR1XS
BL-41 NHvpdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLSTWM2OD1yLkW2PFg6KM7:TR?= NE\p[YNUSU6JRWK=
LU-134-A MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNUewO|Mh|ryP Mn;kV2FPT0WU
SIG-M5 M2PVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;nTWM2OD1yLkW3PFQ5KM7:TR?= NYHvd2FHW0GQR1XS
ONS-76 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X3WWlEPTB;MD61PFI1OiEQvF2= NWTPelVyW0GQR1XS
KARPAS-299 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rmNWlEPTB;MD61PFUxPCEQvF2= Mn3oV2FPT0WU
DU-4475 NYTXdHo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr2VWtKSzVyPUCuOVg4ODNizszN MnjXV2FPT0WU
NB69 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzBTWM2OD1yLkW5PFI2KM7:TR?= Mnn6V2FPT0WU
MHH-PREB-1 M2e5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHRZlNoUUN3ME2wMlYxPzF7IN88US=> M2rRVnNCVkeHUh?=
LU-165 M1LqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnhTWM2OD1yLk[xPFEzKM7:TR?= M1LGN3NCVkeHUh?=
LOUCY NF3KV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HEfGlEPTB;MD62N|M3PCEQvF2= M4LGbnNCVkeHUh?=
NCI-H526 NV6zTpNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPWTWM2OD1yLk[zOVQyKM7:TR?= NIfBcGdUSU6JRWK=
KE-37 M{HxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{KxRmlEPTB;MD62OFI4PiEQvF2= Ml;XV2FPT0WU
NALM-6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXPTWM2OD1yLk[0PFYh|ryP M4q2XnNCVkeHUh?=
CW-2 NEPyeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNkW3PVQh|ryP M2TBc3NCVkeHUh?=
SU-DHL-1 M3zlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETMWI1KSzVyPUCuOlU6PDdizszN MXHTRW5ITVJ?
NB13 NYTpPI5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSxVIVHUUN3ME2wMlY3QDF5IN88US=> M3zZbHNCVkeHUh?=
QIMR-WIL NYDHSWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXOfo1{UUN3ME2wMlY5OzR|IN88US=> M{Dkb3NCVkeHUh?=
ECC12 M4LwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoflTWM2OD1yLkewNFg3KM7:TR?= M4TjTXNCVkeHUh?=
KALS-1 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSzS5hKSzVyPUCuO|A1QTJizszN M4nzfHNCVkeHUh?=
COR-L279 NF[xXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfNe21WUUN3ME2wMlcxQTl4IN88US=> M3\yRnNCVkeHUh?=
NB14 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXq[3lKUUN3ME2wMlczPjF5IN88US=> NGLuXmRUSU6JRWK=
CCRF-CEM NXTZdYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnJTWM2OD1yLke0OlYyKM7:TR?= NFnEXXpUSU6JRWK=
SW954 NIrGRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD1yLke1PVk6KM7:TR?= M1jNSXNCVkeHUh?=
IST-SL1 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rXR2lEPTB;MD63O|M1QCEQvF2= M2f2NXNCVkeHUh?=
LAMA-84 NWrC[3M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWyTWM2OD1yLke3OVY4KM7:TR?= M1zrSnNCVkeHUh?=
Daudi MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwN{e2PFEh|ryP MXjTRW5ITVJ?
BC-3 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILGSm5KSzVyPUCuO|g{ODhizszN MlTGV2FPT0WU
HCC2998 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33l[WlEPTB;MD63PFM3KM7:TR?= MWnTRW5ITVJ?
NCI-H69 MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvSTWM2OD1yLkiwNVQ4KM7:TR?= MmLxV2FPT0WU
CPC-N NHXmZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PZbGlEPTB;MD64NFUzPCEQvF2= MoXRV2FPT0WU
NOMO-1 NFn3SFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXnelM{UUN3ME2wMlgyODh2IN88US=> NV;adpR{W0GQR1XS
CESS Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml71TWM2OD1yLkixNVk4KM7:TR?= M{ntfHNCVkeHUh?=
LC4-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITnSlFKSzVyPUCuPFQxODdizszN NHfjRXdUSU6JRWK=
BL-70 NF\LNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwOEW3NFIh|ryP MWHTRW5ITVJ?
ES4 M4LVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PNTGlEPTB;MD64OVg3QCEQvF2= MYnTRW5ITVJ?
HCE-T NEDvO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rpPWlEPTB;MD64O|E4OSEQvF2= MVjTRW5ITVJ?
JAR NF3RPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTMTWM2OD1yLki3PFI4KM7:TR?= NHvj[pNUSU6JRWK=
ST486 M1PLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH32WnRKSzVyPUCuPFc6OTdizszN M{LRNnNCVkeHUh?=
KS-1 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLiTWM2OD1yLki4NFk3KM7:TR?= MX7TRW5ITVJ?
GDM-1 M{DLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DIbmlEPTB;MD64PFY5PyEQvF2= M3\UR3NCVkeHUh?=
EHEB M1Ptb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jwb2lEPTB;MD65NlU5PSEQvF2= NHfDXItUSU6JRWK=
LB2518-MEL M3Tmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXQT5FkUUN3ME2wMlk{Ojh2IN88US=> M3vCVHNCVkeHUh?=
GOTO NYTDNo44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOzTWM2OD1yLkm1NFc3KM7:TR?= MXvTRW5ITVJ?
LXF-289 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPYTWM2OD1yLkm1PVAyKM7:TR?= NYXiZpNmW0GQR1XS
ES6 M{DQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPITWM2OD1yLkm2OFM4KM7:TR?= NW\he5liW0GQR1XS
OS-RC-2 M1vIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjRVJJKSzVyPUCuPVY5OyEQvF2= NUDiOHVlW0GQR1XS
DMS-153 NWfReG9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HGbGlEPTB;MD65O|Q3QSEQvF2= NW\YS3N{W0GQR1XS
SK-PN-DW NUPibINVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwOUe4N|Eh|ryP MW\TRW5ITVJ?
HH M2n6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:xPGV1UUN3ME2wMlk5QTV7IN88US=> MlHkV2FPT0WU
SH-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofRTWM2OD1zLkCyOFEh|ryP MXfTRW5ITVJ?
MOLT-4 M1nRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwMEO0OVQh|ryP NF\XN4hUSU6JRWK=
TGW NHTDfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPRXVlKSzVyPUGuNFc3PzVizszN NF75O2JUSU6JRWK=
L-540 NELPSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwMUC2NFQh|ryP M3\4RnNCVkeHUh?=
PF-382 NGjUc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwMUG1NVMh|ryP MnrlV2FPT0WU
LC-1F MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ZTWM2OD1zLkGyNFA4KM7:TR?= Mn\vV2FPT0WU
OVCAR-4 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXNWFF5UUN3ME2xMlE{OTZ3IN88US=> NVnGRWliW0GQR1XS
A4-Fuk MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX2e|BKSzVyPUGuNVU{PjRizszN MoDyV2FPT0WU
HCC2218 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFwMU[2OFEh|ryP MV;TRW5ITVJ?
HAL-01 NFi0RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTvXHlKSzVyPUGuNVY6PDNizszN MXfTRW5ITVJ?
IST-MEL1 M1q3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHUTWM2OD1zLkG3OlU6KM7:TR?= NHHiWZBUSU6JRWK=
NCI-H719 NVztTGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3xTWM2OD1zLkG3PFk5KM7:TR?= NGDlR2xUSU6JRWK=
EVSA-T MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LGXWlEPTB;MT6xPFEyPCEQvF2= MWnTRW5ITVJ?
SK-NEP-1 M1rXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi2cVlSUUN3ME2xMlIxOjZ4IN88US=> M4f1VXNCVkeHUh?=
OCUB-M NVTmSWNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvLdFVKSzVyPUGuNlE1QDlizszN Moj0V2FPT0WU
MEG-01 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe2TWM2OD1zLkKyNVE5KM7:TR?= NYPpOoxFW0GQR1XS
no-10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXCVIFKSzVyPUGuNlMyOTJizszN MmXKV2FPT0WU
MHH-CALL-2 NYLTUJBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL0N403UUN3ME2xMlI1PzJzIN88US=> NU[4[mNPW0GQR1XS
SK-N-DZ NVfYc|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\QUmlEPTB;MT6yOFc4PiEQvF2= NHPqfVJUSU6JRWK=
SCLC-21H MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvGR3ZjUUN3ME2xMlI3PDd6IN88US=> MkW3V2FPT0WU
CTV-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwMke0NlUh|ryP NXnESWVyW0GQR1XS
NB1 NXn4U3pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMke3N|Ih|ryP NUG2TIpGW0GQR1XS
NCI-H64 NYLP[IZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXvTWM2OD1zLkK4OFYzKM7:TR?= NIHiXGVUSU6JRWK=
MDA-MB-134-VI NVXzT4xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LRTmlEPTB;MT6yPFU4PyEQvF2= MmHLV2FPT0WU
LB2241-RCC MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwMki2OlMh|ryP NXPOT2RzW0GQR1XS
8-MG-BA NHLNOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLSfIpXUUN3ME2xMlI5QDZ4IN88US=> NXHCSFlYW0GQR1XS
LP-1 M2PabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[wfYNKSzVyPUGuNlk6PDdizszN NHTZd|BUSU6JRWK=
LS-411N MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfpdGFKSzVyPUGuN|A6QThizszN MmW5V2FPT0WU
CAL-148 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrJTYI{UUN3ME2xMlMzPTR{IN88US=> NXXGc4JWW0GQR1XS
NCI-H2171 NE\UToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfBXnpYUUN3ME2xMlM1PTB{IN88US=> MoDwV2FPT0WU
JiyoyeP-2003 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXOTWM2OD1zLkO1N|kh|ryP NVfaN2FOW0GQR1XS
NCI-H2107 NHjQcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwM{W4PFMh|ryP NHn1[|ZUSU6JRWK=
BB30-HNC NF7C[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwM{i5O|gh|ryP MWjTRW5ITVJ?
K-562 M1XQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPyOVNKSzVyPUGuN|kzOTlizszN MkfsV2FPT0WU
PSN1 NUDZ[pV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT3NGFRUUN3ME2xMlQzOjh5IN88US=> MmHRV2FPT0WU
HCC2157 M1LpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nDWmlEPTB;MT60NlY6OSEQvF2= NEf0SZRUSU6JRWK=
SBC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G1S2lEPTB;MT60Nlc1OSEQvF2= NX;HcHZTW0GQR1XS
MC116 M4Hubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwNEO2NVUh|ryP NUjTN3BzW0GQR1XS
KARPAS-422 M37FZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHGXmpKSzVyPUGuOFU{PThizszN MVPTRW5ITVJ?
LB996-RCC MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwNEexNFMh|ryP NGe3[WhUSU6JRWK=
MSTO-211H NGnZTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTN[2lLUUN3ME2xMlQ4QTh5IN88US=> NFjnPVBUSU6JRWK=
BT-474 NXL2emZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\MSmlEPTB;MT61NVc3PCEQvF2= NVXzXI15W0GQR1XS
A388 M16xZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rXeGlEPTB;MT61NVk1PSEQvF2= M3zzRnNCVkeHUh?=
SJSA-1 M3\YcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjQ[5NKSzVyPUGuOVIzPiEQvF2= M3LwVXNCVkeHUh?=
COLO-829 NHrX[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\wV2lEPTB;MT61N|U3PCEQvF2= NEiyRlRUSU6JRWK=
KM-H2 NXT2fGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HETmlEPTB;MT61OlY4KM7:TR?= M{HQ[nNCVkeHUh?=
GR-ST M3r5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3UUJV2UUN3ME2xMlU3QDJizszN NXWxOGtsW0GQR1XS
RPMI-8866 NI\JPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfqUXI4UUN3ME2xMlYxOTR2IN88US=> NH7CclRUSU6JRWK=
KG-1 NUfPOocxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;yXGR4UUN3ME2xMlYyQTBzIN88US=> MkK5V2FPT0WU
NCI-H82 NFe0VmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonSTWM2OD1zLk[zOFA3KM7:TR?= M3nHRnNCVkeHUh?=
LB1047-RCC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPOWIRKSzVyPUGuOlM1PTlizszN MXvTRW5ITVJ?
KM12 M{K0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\MTWM2OD1zLk[0O{DPxE1? M2K0VnNCVkeHUh?=
NB5 NXLQOlhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[1bGlEPTB;MT62OVY4PyEQvF2= MXfTRW5ITVJ?
HDLM-2 NHHiTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP0TWM2OD1zLk[4NlgyKM7:TR?= M2C4OnNCVkeHUh?=
KU812 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwNkm2NFUh|ryP Mlz3V2FPT0WU
DB Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi3NIJ7UUN3ME2xMlcxOzV|IN88US=> NWDBR2RsW0GQR1XS
HD-MY-Z M{fwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfWZ2FFUUN3ME2xMlc2OjN2IN88US=> NYDXcVNjW0GQR1XS
KURAMOCHI Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwN{eyNFch|ryP M1O4[3NCVkeHUh?=
ETK-1 NIH5XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO0TWM2OD1zLke4PFc6KM7:TR?= NHHXRWFUSU6JRWK=
SK-UT-1 NW\Hem9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfZflJKSzVyPUGuO|k{QDhizszN M{PPVHNCVkeHUh?=
HUTU-80 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjvTWM2OD1zLke5OVA5KM7:TR?= NVrB[FNyW0GQR1XS
ES7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPwPG5KSzVyPUGuPFA{ODJizszN MVrTRW5ITVJ?
SW872 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjVXnFCUUN3ME2xMlgyOzl3IN88US=> Mm\sV2FPT0WU
TK10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknSTWM2OD1zLkizNVA5KM7:TR?= NVXSTVFNW0GQR1XS
LB831-BLC NXi0S3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHne5VKSzVyPUGuPFM2PjNizszN MXfTRW5ITVJ?
TE-9 MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwOES0NlIh|ryP MnzlV2FPT0WU
MLMA M1HoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvtS2VKSzVyPUGuPFgzOzRizszN NXnPdI1[W0GQR1XS
D-542MG Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP1TXR3UUN3ME2xMlg6Ozd|IN88US=> M2DjRnNCVkeHUh?=
EW-16 NYO3NZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;0W4tKSzVyPUGuPVI4OiEQvF2= MVTTRW5ITVJ?
LOXIMVI MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TBUGlEPTB;MT65N|I5KM7:TR?= NWPGc5M4W0GQR1XS
GB-1 M3\Temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwOUO4OlYh|ryP MX;TRW5ITVJ?
IST-SL2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq4Voc{UUN3ME2yMlAxOjZ{IN88US=> NUGxcFd{W0GQR1XS
LAN-6 M1qzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTMWGtbUUN3ME2yMlAyQTZ4IN88US=> Mo\zV2FPT0WU
NCI-H510A M4foZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;6d2lEPTB;Mj6wOFUxOiEQvF2= NEnLc2VUSU6JRWK=
NCI-H1092 NWjhOFFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fpUGlEPTB;Mj6wOVEzPCEQvF2= M3noSXNCVkeHUh?=
HT NWP4ZYw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwMUC0OVQh|ryP M1;KXnNCVkeHUh?=
RL95-2 NGjVUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDdmlEPTB;Mj6xNVQ5OiEQvF2= NYK4e2RSW0GQR1XS
NCI-H1355 NUjze21XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16wT2lEPTB;Mj6xNVc6OiEQvF2= MYTTRW5ITVJ?
NCI-H720 NHLKcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjLfppKSzVyPUKuNVY5PzNizszN NXTrW3hrW0GQR1XS
NCI-H1522 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvPTWM2OD1{LkKxO|I{KM7:TR?= M{XvXnNCVkeHUh?=
LB373-MEL-D NHHCclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[1TWM2OD1{LkK2PVAzKM7:TR?= MYHTRW5ITVJ?
DG-75 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrJcYxJUUN3ME2yMlI4OTR6IN88US=> NYnoTWRNW0GQR1XS
ML-2 NWq3R41YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLjTWM2OD1{LkOyPFU2KM7:TR?= NWDXXZdrW0GQR1XS
SF126 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJwM{OwPVQh|ryP NXvS[2RLW0GQR1XS
MPP-89 NVXFfIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDaTWM2OD1{LkOzNVQ2KM7:TR?= NX\UZm1kW0GQR1XS
NCI-H345 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJwM{OyO|ch|ryP MlPrV2FPT0WU
LS-123 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PnPGlEPTB;Mj6zOFk{PiEQvF2= M4CzR3NCVkeHUh?=
NB10 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfvTWM2OD1{LkSxNFkzKM7:TR?= NGTZb3BUSU6JRWK=
CGTH-W-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwNEKyOlch|ryP MV;TRW5ITVJ?
CP66-MEL NUPCeZVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XWR2lEPTB;Mj60O|c4KM7:TR?= Ml[wV2FPT0WU
L-428 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn0R4JKSzVyPUKuOFg2OjFizszN NVHyWFZbW0GQR1XS
DMS-79 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvDN|VKSzVyPUKuOVQyODNizszN MV3TRW5ITVJ?
NCI-H1882 NFi2OVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDVXFJKSzVyPUKuOlc2PjJizszN M3XyeHNCVkeHUh?=
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xO3FKSzVyPUKuO|Y5PzZizszN NHPycoZUSU6JRWK=
EW-1 NYLxVolFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDr[WFrUUN3ME2yMlc4ODh|IN88US=> NXv0foVpW0GQR1XS
U-266 M3fjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwOES4NlMh|ryP MnW2V2FPT0WU
COLO-320-HSR M4TBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvJTWM2OD1{Lki1OlQyKM7:TR?= NInGZ5pUSU6JRWK=
KMOE-2 NYH3fVhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJwOEe3NVEh|ryP NUPLTmU3W0GQR1XS
BB49-HNC M3y0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJwOUK0PEDPxE1? M4f4cXNCVkeHUh?=
GI-1 M3f4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm4dohKSzVyPUKuPVI6PTdizszN NGLkXppUSU6JRWK=
NCI-H1304 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNwMEC1NVEh|ryP MoLNV2FPT0WU
NCI-H2227 NGjlSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLmTFVqUUN3ME2zMlAzODd7IN88US=> M3;mXHNCVkeHUh?=
U-87-MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX5enVKSzVyPUOuNFM2OTNizszN MlzzV2FPT0WU
NCI-H747 M4LiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInQNWRKSzVyPUOuNFUzODZizszN MX7TRW5ITVJ?
CTB-1 NIHiTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTNwMEWzO|Yh|ryP MkDvV2FPT0WU
RPMI-8226 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNwMUSzO|gh|ryP MlLwV2FPT0WU
NCI-H2141 NHHN[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL0TWM2OD1|LkG2OVY3KM7:TR?= MVfTRW5ITVJ?
IST-MES1 NW\2UVRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3hTWM2OD1|LkG4Nlc6KM7:TR?= NVr6XnVNW0GQR1XS
TE-5 NFfj[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTNwMkGzOFIh|ryP MYHTRW5ITVJ?
UACC-257 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ETWM2OD1|LkSzOlU6KM7:TR?= M{f1XnNCVkeHUh?=
SK-N-FI NGXNN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HzZmlEPTB;Mz60OVIzPyEQvF2= NHv4NmJUSU6JRWK=
MFH-ino NWTq[IRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwNE[1PFkh|ryP MlfEV2FPT0WU
SF268 NXLUN4ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfZNYdKSzVyPUOuOFgyPzRizszN MnXNV2FPT0WU
TE-12 M2XYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLtUI5KSzVyPUOuOVE3QTlizszN M1vCWHNCVkeHUh?=
NB6 NYTyelhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fhNmlEPTB;Mz61OVU3OyEQvF2= NVTMXYVvW0GQR1XS
DJM-1 M1zOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG2O29KSzVyPUOuOVk5QTlizszN NH7HZ2tUSU6JRWK=
MZ1-PC MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nWbmlEPTB;Mz62NVYzPCEQvF2= NWO1XYhuW0GQR1XS
OCI-AML2 NEfWUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XFcWlEPTB;Mz62NlY4OSEQvF2= MlzlV2FPT0WU
NCI-H1155 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO0TWM2OD1|LkewPVQ4KM7:TR?= NH\Fe2pUSU6JRWK=
RKO NEPjT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNwN{exPFkh|ryP MXjTRW5ITVJ?
ECC4 NWDBSpdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\SdGlEPTB;Mz65O|E6PSEQvF2= Mlf3V2FPT0WU
BB65-RCC NWjtXGVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvFUpNKSzVyPUOuPVc2PDdizszN NV\uVIdSW0GQR1XS
EB-3 NFnrW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTxTYpsUUN3ME2zMlk6PjN|IN88US=> NYLCO|VnW0GQR1XS
SHP-77 NF3ZTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjKTWM2OD12LkCwOVI1KM7:TR?= MlXpV2FPT0WU
NCI-H2196 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwMEW2NlUh|ryP NWLSWnFXW0GQR1XS
GI-ME-N MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzvRolKSzVyPUSuNFY{QTlizszN MXfTRW5ITVJ?
MN-60 M2jGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrCRY9KSzVyPUSuNVA5PyEQvF2= NXXvNFBDW0GQR1XS
NCI-H1694 M{LpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRwMUO0NFUh|ryP NV;LR4U5W0GQR1XS
LU-65 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzVWo9KSzVyPUSuNVU{OzJizszN NELZbFRUSU6JRWK=
NCI-H1436 NHv4dmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHOUI1KSzVyPUSuNVg{OzNizszN NHjIfllUSU6JRWK=
KINGS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXBZolKSzVyPUSuN|E1OzJizszN MofVV2FPT0WU
GT3TKB NHLaXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrkTWM2OD12LkOzNlY5KM7:TR?= NVuxb5RVW0GQR1XS
Becker MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDMZldMUUN3ME20MlM4OzF{IN88US=> Mny5V2FPT0WU
HCC1187 NVK3d4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37hcmlEPTB;ND64PVY2PyEQvF2= MXPTRW5ITVJ?
D-502MG NUntZ2lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX6SW5KSzVyPUWuNFA1OTZizszN NIqxOZhUSU6JRWK=
VA-ES-BJ MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHhdnlKSzVyPUWuNVM4PzhizszN MVTTRW5ITVJ?
NB7 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHWZlZKSzVyPUWuNVQyOTJizszN M1vXS3NCVkeHUh?=
SW962 M{LRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTVwM{i4NVQh|ryP M1[5fHNCVkeHUh?=
no-11 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\NTWM2OD13Lke2N|Q{KM7:TR?= NXrMdnZtW0GQR1XS
KNS-81-FD MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPO[HVKSzVyPUWuPVA3QTRizszN NWO0TpVXW0GQR1XS
COLO-684 NX;KUZFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HESGlEPTB;NT65PVQ6PCEQvF2= M{XMfXNCVkeHUh?=
D-263MG NVO5Xo9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLTWM2OD14LkC4PFk2KM7:TR?= NFPCZXVUSU6JRWK=
EW-24 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Ed3liUUN3ME22MlI5PTFizszN NEDuO2xUSU6JRWK=
TE-10 M3XPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfjR|lKSzVyPU[uOFI3OjNizszN MUPTRW5ITVJ?
EKVX M4r4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTZwNE[zNlEh|ryP MUDTRW5ITVJ?
NCI-H1648 NWnOXnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3TclZKSzVyPU[uOlc2PTdizszN NX:2RmozW0GQR1XS
LB771-HNC MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTUTWM2OD14LkmyN|AyKM7:TR?= MlrLV2FPT0WU
SK-MEL-1 M{e5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRThwMUOxOlYh|ryP MmjDV2FPT0WU
COLO-668 NEjab2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\oTWM2OD16LkK3O|g3KM7:TR?= NGe3VZlUSU6JRWK=
EW-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f1c2lEPTB;OD60NFgxOyEQvF2= MUjTRW5ITVJ?
A253 NGfvd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRThwOES2OlEh|ryP M{fHU3NCVkeHUh?=
NCI-H2126 NHTkXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XuVWlEPTB;OD64PVMyQSEQvF2= M{Lre3NCVkeHUh?=
Calu-6 NV75TI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHOUmZKSzVyPUiuPVkxPDJizszN M33DSHNCVkeHUh?=
NCI-H23 M1zMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[4TWM2OD17LkG3O|Q3KM7:TR?= MkjGV2FPT0WU
WSU-NHL MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILpbWtKSzVyPUmuO|c1PzhizszN M1HxNnNCVkeHUh?=
MMAC-SF Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLpTIRKSzVyPUmuPVc6ODRizszN M3vIVXNCVkeHUh?=
SK-LMS-1 NHjMbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7aTWM2OD1zMD6yPFM1KM7:TR?= MWDTRW5ITVJ?
GCIY NYTlVIFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDzXoVKSzVyPUGwMlU6OjRizszN NUXpW|VjW0GQR1XS
TE-15 NFjvTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFzLk[wNFQh|ryP NH3uW4FUSU6JRWK=
EoL-1-cell NXT6SohST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnn[mRKSzVyPUGxMlc3QDJizszN NEK3VnlUSU6JRWK=
NCI-H2081 M3zYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHROIFXUUN3ME2xNU44Pzh4IN88US=> M2TaUHNCVkeHUh?=
EW-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG1TWM2OD1zMj6yOFY{KM7:TR?= MVrTRW5ITVJ?
CAS-1 M4GzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP2TWM2OD1zMj6zOlMyKM7:TR?= M{DxcHNCVkeHUh?=
C2BBe1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD4Z2cxUUN3ME2xNk43OTNzIN88US=> MlqwV2FPT0WU
D-247MG M2PWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfzTWM2OD1zMj63PVUzKM7:TR?= NGTCbJRUSU6JRWK=
NCI-SNU-5 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF{LkiwNVMh|ryP NYTo[XJkW0GQR1XS
LS-1034 NWP1S|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojaTWM2OD1zND6zPVc2KM7:TR?= NWTK[3JqW0GQR1XS
EW-18 M{DMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjjdJZCUUN3ME2xOE41PDhizszN M4PsbXNCVkeHUh?=
Raji M1SwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;sfm5KSzVyPUG0MlUxPDlizszN NFrPZYVUSU6JRWK=
D-283MED M4jNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHwTWM2OD1zND62NlcyKM7:TR?= NHrCWW5USU6JRWK=
MZ2-MEL NHvY[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G4eGlEPTB;MUSuPVY6PiEQvF2= MkD5V2FPT0WU
NCI-SNU-16 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3oOG5qUUN3ME2xOU41PjN|IN88US=> Mnm1V2FPT0WU
P30-OHK NEP4UGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF5Lke4N|Eh|ryP MljHV2FPT0WU
RXF393 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPzTWM2OD1zOT6wNVg3KM7:TR?= NYDCZYp2W0GQR1XS
NCI-H1395 M{jzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X4V2lEPTB;MkCuOlcxOyEQvF2= NE\pT2FUSU6JRWK=
U-698-M NIC1dGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJyLkewO|Uh|ryP MoDrV2FPT0WU
NCI-SNU-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn2TWM2OD1{MD63NlI{KM7:TR?= M{TQ[3NCVkeHUh?=
SW684 M{\hOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWzc|dZUUN3ME2yNU4yPzF4IN88US=> NVrIUVFRW0GQR1XS
NCI-H716 NGr4[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPFfJpKSzVyPUKxMlMyPTRizszN MWLTRW5ITVJ?
JVM-2 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX3N41YUUN3ME2yNU41OTN|IN88US=> NInOPXZUSU6JRWK=
NCI-H1581 M4\1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvsTWM2OD1{Mj60NVQ5KM7:TR?= MnrLV2FPT0WU
CA46 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnETWM2OD1|MT62PVM3KM7:TR?= NEXUNFhUSU6JRWK=
SNB75 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3cGhKSzVyPUOzMlY2ODNizszN NF3RU29USU6JRWK=
KNS-42 Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjGbolnUUN3ME2zOU46PjJ2IN88US=> NGjRV4JUSU6JRWK=
TUR NEXOdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTvTWM2OD1|Nj6wOVIyKM7:TR?= MnjvV2FPT0WU
REH M{PSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD1|Nz64NlEyKM7:TR?= M4fmS3NCVkeHUh?=
EW-22 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELnUHhKSzVyPUSyMlI5QDVizszN M3XWZnNCVkeHUh?=
NCI-H446 NXvCbJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDpdFlKSzVyPUSyMlc5PTNizszN MWjTRW5ITVJ?
ES3 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnyfm1KSzVyPUSzMlE{OzlizszN NV7VNXJDW0GQR1XS
EW-11 NYS1cW1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPXc2M1UUN3ME20OE45OjF6IN88US=> MYDTRW5ITVJ?
RH-1 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr5bI9KSzVyPUS3MlU5OTJizszN MnS3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2
NCT03838042 Not yet recruiting CNS Tumor|Solid Tumor University Hospital Heidelberg|German Cancer Research Center March 2019 Phase 1|Phase 2
NCT03829930 Not yet recruiting Prostate Adenocarcinoma George Washington University March 1 2019 Phase 1
NCT03765229 Recruiting Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID